|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: MPP6 |
Gene summary for MPP6 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | MPP6 | Gene ID | 51678 |
| Gene name | protein associated with LIN7 2, MAGUK family member | |
| Gene Alias | MPP6 | |
| Cytomap | 7p15.3 | |
| Gene Type | protein-coding | GO ID | GO:0008150 | UniProtAcc | A0A024RA25 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 51678 | MPP6 | LZE24T | Human | Esophagus | ESCC | 1.35e-02 | 1.47e-01 | 0.0596 |
| 51678 | MPP6 | P2T-E | Human | Esophagus | ESCC | 1.60e-11 | 2.23e-01 | 0.1177 |
| 51678 | MPP6 | P4T-E | Human | Esophagus | ESCC | 1.67e-10 | 2.90e-01 | 0.1323 |
| 51678 | MPP6 | P8T-E | Human | Esophagus | ESCC | 1.05e-05 | 1.09e-01 | 0.0889 |
| 51678 | MPP6 | P9T-E | Human | Esophagus | ESCC | 1.15e-06 | 1.32e-01 | 0.1131 |
| 51678 | MPP6 | P10T-E | Human | Esophagus | ESCC | 6.67e-08 | 1.33e-01 | 0.116 |
| 51678 | MPP6 | P11T-E | Human | Esophagus | ESCC | 2.28e-03 | 1.70e-01 | 0.1426 |
| 51678 | MPP6 | P15T-E | Human | Esophagus | ESCC | 1.96e-06 | 7.95e-02 | 0.1149 |
| 51678 | MPP6 | P16T-E | Human | Esophagus | ESCC | 6.26e-12 | 1.44e-01 | 0.1153 |
| 51678 | MPP6 | P20T-E | Human | Esophagus | ESCC | 2.48e-03 | 1.53e-01 | 0.1124 |
| 51678 | MPP6 | P21T-E | Human | Esophagus | ESCC | 1.00e-05 | 4.27e-02 | 0.1617 |
| 51678 | MPP6 | P22T-E | Human | Esophagus | ESCC | 1.57e-17 | 2.16e-01 | 0.1236 |
| 51678 | MPP6 | P23T-E | Human | Esophagus | ESCC | 2.87e-07 | 1.70e-01 | 0.108 |
| 51678 | MPP6 | P24T-E | Human | Esophagus | ESCC | 5.48e-03 | 1.15e-01 | 0.1287 |
| 51678 | MPP6 | P26T-E | Human | Esophagus | ESCC | 3.83e-14 | 3.05e-01 | 0.1276 |
| 51678 | MPP6 | P27T-E | Human | Esophagus | ESCC | 1.07e-12 | 1.72e-01 | 0.1055 |
| 51678 | MPP6 | P28T-E | Human | Esophagus | ESCC | 2.17e-07 | 2.19e-01 | 0.1149 |
| 51678 | MPP6 | P30T-E | Human | Esophagus | ESCC | 5.41e-09 | 3.42e-01 | 0.137 |
| 51678 | MPP6 | P32T-E | Human | Esophagus | ESCC | 7.54e-08 | 2.06e-01 | 0.1666 |
| 51678 | MPP6 | P37T-E | Human | Esophagus | ESCC | 1.97e-11 | 2.97e-01 | 0.1371 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Prostate |  | BPH: Benign Prostatic Hyperplasia |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| MPP6 | SNV | Missense_Mutation | c.991N>T | p.Ala331Ser | p.A331S | Q9NZW5 | protein_coding | deleterious(0.01) | possibly_damaging(0.715) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| MPP6 | SNV | Missense_Mutation | c.235N>A | p.Glu79Lys | p.E79K | Q9NZW5 | protein_coding | deleterious(0.02) | possibly_damaging(0.85) | TCGA-A8-A094-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPP6 | SNV | Missense_Mutation | novel | c.22C>A | p.Leu8Ile | p.L8I | Q9NZW5 | protein_coding | tolerated(0.19) | benign(0.12) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| MPP6 | SNV | Missense_Mutation | c.659T>G | p.Val220Gly | p.V220G | Q9NZW5 | protein_coding | deleterious(0) | probably_damaging(0.974) | TCGA-C5-A7UE-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | SD | |
| MPP6 | SNV | Missense_Mutation | c.961C>T | p.Arg321Cys | p.R321C | Q9NZW5 | protein_coding | deleterious(0) | probably_damaging(0.962) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| MPP6 | SNV | Missense_Mutation | c.682N>A | p.Pro228Thr | p.P228T | Q9NZW5 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-A6-A566-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | PD | |
| MPP6 | SNV | Missense_Mutation | c.211A>G | p.Ile71Val | p.I71V | Q9NZW5 | protein_coding | tolerated(0.42) | benign(0.001) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| MPP6 | SNV | Missense_Mutation | c.347C>A | p.Ser116Tyr | p.S116Y | Q9NZW5 | protein_coding | deleterious(0.04) | benign(0.006) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| MPP6 | SNV | Missense_Mutation | c.384N>G | p.Ile128Met | p.I128M | Q9NZW5 | protein_coding | deleterious(0) | benign(0.418) | TCGA-AA-A010-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Chemotherapy | folinic | CR | |
| MPP6 | SNV | Missense_Mutation | rs200954257 | c.1370N>T | p.Ala457Val | p.A457V | Q9NZW5 | protein_coding | deleterious(0.02) | probably_damaging(0.947) | TCGA-AZ-4315-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |